Literature DB >> 26420596

Extended versus limited pelvic lymph node dissection during bilateral nerve-sparing radical prostatectomy and its effect on continence and erectile function recovery: long-term results and trifecta rates of a comparative analysis.

Georgios Hatzichristodoulou1, Stefan Wagenpfeil2, Gudrun Wagenpfeil2, Tobias Maurer3, Thomas Horn3, Kathleen Herkommer3, Marie Hegemann3, Jürgen E Gschwend3, Hubert Kübler3.   

Abstract

PURPOSE: To assess continence and erectile function (EF) recovery of extended pelvic lymph node dissection (ePLND) versus limited PLND (lPLND) after bilateral nerve-sparing radical prostatectomy (BNSRP).
METHODS: Consecutive prostate cancer (PCa) patients undergoing BNSRP were stratified according to D'Amico into two groups: low-risk-PCa lPLND (obturator) and intermediate-/high-risk-PCa ePLND (obturator, external iliac artery, internal iliac artery, common iliac artery). Continence (no pad/one safety pad) and EF (IIEF-5 ≥ 17) recovery were assessed. Patients with phosphodiesterase type 5 inhibitors, neoadjuvant/adjuvant therapy, positive lymph nodes or positive surgical margins were excluded.
RESULTS: From January 2007 to May 2012, a total 966 consecutive patients were included. Four hundred and sixty patients met the inclusion/exclusion criteria: 262 patients had ePLND and 198 patients had lPLND. Mean number of lymph nodes was 20.4 (range 10-65) and 4.7 (range 0-10), respectively (p < 0.001). Continence and spontaneous EF recovery after 12 months were 89.7 versus 93.4 % and 40.4 versus 47.5 %, respectively (all p > 0.05). Patient age at surgery (p = 0.001), preoperative EF (p < 0.001) and pathological tumor stage (p = 0.008), but not ePLND (p = 0.561), were independent predictors of EF recovery. No association was detected for continence recovery. Seven-year BCR-free survival for pT2 PCa was 100 and 94.8 % in lPLND and ePLND, respectively (p = 0.011). For pT3 PCa, this was 94.7 and 81.2 %, respectively (p = 0.287). At 2 years, the trifecta of continence, potency and recurrence freedom was achieved in 47.5 and 44.1 % in lPLND and ePLND, respectively (p = 0.451).
CONCLUSIONS: ePLND is not associated with increased risk of postoperative incontinence or erectile dysfunction. Only patient age at surgery, preoperative EF and pathological tumor stage represent predictors of EF recovery.

Entities:  

Keywords:  Continence; Erectile function; Extended lymph node dissection; Radical prostatectomy; Trifecta

Mesh:

Year:  2015        PMID: 26420596     DOI: 10.1007/s00345-015-1699-9

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  26 in total

Review 1.  Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy.

Authors:  Vincenzo Ficarra; Giacomo Novara; Thomas E Ahlering; Anthony Costello; James A Eastham; Markus Graefen; Giorgio Guazzoni; Mani Menon; Alexandre Mottrie; Vipul R Patel; Henk Van der Poel; Raymond C Rosen; Ashutosh K Tewari; Timothy G Wilson; Filiberto Zattoni; Francesco Montorsi
Journal:  Eur Urol       Date:  2012-06-01       Impact factor: 20.096

2.  Nerve-sparing approach during radical prostatectomy is strongly associated with the rate of postoperative urinary continence recovery.

Authors:  Nazareno Suardi; Marco Moschini; Andrea Gallina; Giorgio Gandaglia; Firas Abdollah; Umberto Capitanio; Marco Bianchi; Manuela Tutolo; Niccolò Passoni; Andrea Salonia; Petter Hedlund; Patrizio Rigatti; Francesco Montorsi; Alberto Briganti
Journal:  BJU Int       Date:  2012-06-21       Impact factor: 5.588

3.  Retraction of external iliac vessels and obturator nerve with the vas deferens during extended pelvic lymph node dissection in robot-assisted radical prostatectomy.

Authors:  Wesley Ludwig; Ashutosh Tewari
Journal:  Urology       Date:  2013-06       Impact factor: 2.649

4.  Comparison of oncological outcomes between retropubic radical prostatectomy and robot-assisted radical prostatectomy: an analysis stratified by surgical experience.

Authors:  Jinsung Park; Dae-Seon Yoo; Cheryn Song; Sahyun Park; Sejun Park; Seong Cheol Kim; Yongmee Cho; Hanjong Ahn
Journal:  World J Urol       Date:  2013-09-24       Impact factor: 4.226

5.  Positive surgical margins after radical prostatectomy: What should we care about?

Authors:  Caroline Pettenati; Yann Neuzillet; Camelia Radulescu; Jean-Marie Hervé; Vincent Molinié; Thierry Lebret
Journal:  World J Urol       Date:  2015-05-05       Impact factor: 4.226

6.  Extended pelvic lymph node dissection does not affect erectile function recovery in patients treated with bilateral nerve-sparing radical prostatectomy.

Authors:  Giorgio Gandaglia; Nazareno Suardi; Andrea Gallina; Firas Abdollah; Umberto Capitanio; Andrea Salonia; Renzo Colombo; Marco Bianchi; Felix K Chun; Jens Hansen; Patrizio Rigatti; Francesco Montorsi; Alberto Briganti
Journal:  J Sex Med       Date:  2012-06-27       Impact factor: 3.802

7.  The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence.

Authors:  A Karl; A Buchner; C Tympner; T Kirchner; U Ganswindt; C Belka; R Ganzer; M Burger; F Eder; F Hofstädter; D Schilling; K Sievert; A Stenzl; M Scharpf; F Fend; F Vom Dorp; H Rübben; K Schmid; D Porres-Knoblauch; A Heidenreich; B Hangarter; R Knüchel-Clarke; M Rogenhofer; B Wullich; A Hartmann; E Comploj; A Pycha; E Hanspeter; D Pehrke; G Sauter; M Graefen; C Stief; A Haese
Journal:  World J Urol       Date:  2015-02-15       Impact factor: 4.226

8.  Oncologic results, functional outcomes, and complication rates of robotic-assisted radical prostatectomy: multicenter experience in Turkey including 1,499 patients.

Authors:  A I Tasci; I Tufek; E Gumus; A E Canda; V Tugcu; F Atug; U Boylu; Z Akbulut; S Sahin; A Simsek; A R Kural
Journal:  World J Urol       Date:  2014-09-13       Impact factor: 4.226

9.  Long-term outcome following radical prostatectomy for Gleason 8-10 prostatic adenocarcinoma.

Authors:  Naveen Pokala; Jerry J Trulson; Majdee Islam
Journal:  World J Urol       Date:  2014-02-09       Impact factor: 4.226

10.  Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy.

Authors:  Trinity J Bivalacqua; Phillip M Pierorazio; Michael A Gorin; Mohamad E Allaf; H Ballentine Carter; Patrick C Walsh
Journal:  Urology       Date:  2013-09       Impact factor: 2.649

View more
  6 in total

Review 1.  Therapeutic Value of Standard Versus Extended Pelvic Lymph Node Dissection During Radical Prostatectomy for High-Risk Prostate Cancer.

Authors:  Michele Colicchia; Vidit Sharma; Firas Abdollah; Alberto Briganti; R Jeffrey Karnes
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

Review 2.  Understanding and Managing Erectile Dysfunction in Patients Treated for Cancer.

Authors:  Maria Voznesensky; Kiran Annam; Karl J Kreder
Journal:  J Oncol Pract       Date:  2016-04       Impact factor: 3.840

3.  Longitudinal recovery patterns of penile length and the underexplored benefit of long-term phosphodiesterase-5 inhibitor use after radical prostatectomy.

Authors:  Young Suk Kwon; Nicholas Farber; Ji Woong Yu; Kevin Rhee; Christopher Han; Patrick Ney; Jeong Hee Hong; Paul Lee; Nikhil Gupta; Wun-Jae Kim; Isaac Yi Kim
Journal:  BMC Urol       Date:  2018-05-09       Impact factor: 2.264

Review 4.  THE ROLE OF LYMPHADENECTOMY IN PROSTATE CANCER PATIENTS.

Authors:  Dean Markić; Romano Oguić; Kristian Krpina; Ivan Vukelić; Gordana Đorđević; Iva Žuža; Josip Španjol
Journal:  Acta Clin Croat       Date:  2019-11       Impact factor: 0.780

Review 5.  Utility of Lymphadenectomy in Prostate Cancer: Where Do We Stand?

Authors:  Bartosz Małkiewicz; Paweł Kiełb; Jakub Karwacki; Róża Czerwińska; Paulina Długosz; Artur Lemiński; Łukasz Nowak; Wojciech Krajewski; Tomasz Szydełko
Journal:  J Clin Med       Date:  2022-04-22       Impact factor: 4.241

6.  Comparison of Functional Outcome after Extended versus Super-Extended Pelvic Lymph Node Dissection during Radical Prostatectomy in High-Risk Localized Prostate Cancer.

Authors:  Heikki Seikkula; Pieter Janssen; Manuela Tutolo; Lorenzo Tosco; Antonino Battaglia; Lisa Moris; Thomas Van den Broeck; Maarten Albersen; Gert De Meerleer; Hendrik Van Poppel; Wouter Everaerts; Steven Joniau
Journal:  Front Oncol       Date:  2017-11-22       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.